Lung Carcinoma Antibody (MOC-1): sc-52342

Lung Carcinoma Antibody (MOC-1) is a mouse monoclonal IgG1 antibody that detects the Lung Carcinoma protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-Lung Carcinoma antibody (MOC-1) is available as a non-conjugated format, providing researchers with a reliable tool for studying this critical protein. The Lung Carcinoma protein plays a significant role in the progression of lung cancer, which is characterized by the uncontrolled growth of lung tissue and is the leading cause of cancer-related deaths worldwide, accounting for approximately 3 million fatalities each year. Understanding the structure of Lung Carcinoma protein is essential, as this protein is often associated with various signaling pathways that regulate cell proliferation and survival. Abnormalities in Lung Carcinoma protein structure can lead to dysregulation of these pathways, contributing to tumorigenesis and metastasis. Lung Carcinoma protein interactions with specific molecules, such as growth factors and receptors, further underscore its importance in cancer biology, as these interactions can influence the behavior of cancer cells and their response to therapies. With the increasing incidence of lung cancer, particularly among women, Lung Carcinoma (MOC-1) antibody serves as a vital resource for advancing research aimed at understanding the mechanisms of this disease and developing targeted treatments.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Lung Carcinoma Antibody (MOC-1) References:

1. Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression.  |  Xu, H., et al. 2004. Hum Pathol. 35: 1419-22. PMID: 15668901
2. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.  |  Sher, YP., et al. 2005. Clin Cancer Res. 11: 173-9. PMID: 15671543
3. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer.  |  Haura, EB., et al. 2006. Clin Lung Cancer. 7: 273-5. PMID: 16512982
4. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer.  |  Jung, CK., et al. 2006. Pathol Int. 56: 503-9. PMID: 16930330
5. Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis.  |  Werle, B., et al. 2006. Oncol Rep. 16: 647-55. PMID: 16969475
6. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer.  |  Chong, IW., et al. 2006. Oncol Rep. 16: 981-8. PMID: 17016581
7. Lung cancer-associated protein: development and characterization of a new assay that detects a circulating lung cancer marker.  |  Maimonis, P., et al. 1991. Cancer Res. 51: 3838-42. PMID: 1855201
8. Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen.  |  Berendsen, HH., et al. 1988. J Clin Pathol. 41: 273-6. PMID: 2834417
9. Detection of the circulating lung cancer marker LCAP with a new monoclonal antibody TRD-L1.  |  Tsuji, K., et al. 1997. Int J Biol Markers. 12: 49-54. PMID: 9342632